Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
Citi
UBS
Accenture
Daiichi Sankyo
McKinsey
AstraZeneca
Covington
Moodys

Generated: August 17, 2017

DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has eighty-eight approved drugs.

There are eighty-six US patents protecting ABBVIE drugs.

There are one thousand four hundred and twenty-four patent family members on ABBVIE drugs in sixty-nine countries.

Summary for Applicant: Abbvie

Patents:86
Tradenames:77
Ingredients:64
NDAs:88
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
NORVIR
ritonavir
POWDER;ORAL209512-001Jun 7, 2017RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-002Nov 5, 2004ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie
CALCIJEX
calcitriol
INJECTABLE;INJECTION018874-002Sep 25, 1986DISCNYesNo► Subscribe► SubscribeY► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION019732-001Jan 26, 1989► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020708-001Mar 7, 1997► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-002May 30, 1997► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-001Dec 22, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBVIE drugs

Drugname Dosage Strength Tradename Submissiondate
lopinavir and ritonavir
Oral Solution80 mg/20 mg per mL
KALETRA
6/19/2014
testosterone
Gel1.62% (1.25 g and 2.5 g packets)
ANDROGEL
6/19/2013
ritonavir
Capsules100 mg
NORVIR
10/31/2012
testosterone
Gel1.62%
ANDROGEL
4/6/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010
clarithromycin
Extended-release Tablet500 mg
BIAXIN XL
12/6/2010
eprosartan mesylate
Tablets400 mg and 600 mg
TEVETEN
5/10/2010
fenofibrate choline
Delayed-release Capsules45 mg
TRILIPIX
9/2/2009
fenofibrate choline
Delayed-release Capsules135 mg
TRILIPIX
9/1/2009
cisatracurium besylate (multi-dose)
     Injection2 mg/mL, 10 mL vial
NIMBEX
8/12/2009
cisatracurium besylate (preserve free)
Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial
NIMBEX
8/4/2009
lopinavir and ritonavir
Tablets100 mg/25 mg
KALETRA
12/23/2008
testosterone
Gel Metered-dose Pump1%
ANDROGEL
12/19/2008
paricalcitol
Injection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials
ZEMPLAR
11/28/2008
paricalcitol
Capsules1 mcg and 2 mcg
ZEMPLAR
10/14/2008
paricalcitol
Capsules4 mcg
ZEMPLAR
8/25/2008
fenofibrate
Tablets48 mg
TRICOR
7/1/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets1 mg/240 mg
TARKA
2/20/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets2 mg/180 mg and 2 mg/240 mg
TARKA
11/9/2007
fenofibrate
Tablets145 mg
TRICOR
10/19/2007
trandolapril and verapamil hydrochloride
Extended-release Tablets4 mg/ 240 mg
TARKA
7/24/2007
hydrocodone bitartrate and ibuprofen
Tablets2.5 mg/200 mg
VICOPROFEN
2/24/2006
hydrocodone bitartrate and ibuprofen
Tablets5 mg/200 mg
VICOPROFEN
5/27/2005
divalproex sodium
Extended-release Tablets500 mg
DEPAKOTE ER
2/8/2005
trandolapril
Tablets1 mg, 2 mg and 4 mg
MAVIK
10/4/2004
divalproex sodium
Extended-release Tablets250 mg
DEPAKOTE ER
5/3/2004

Non-Orange Book Patents for Abbvie

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,428,814 Bioadhesive nanoparticulate compositions having cationic surface stabilizers► Subscribe
6,558,679 Container for an inhalation anesthetic► Subscribe
7,288,267Bioadhesive nanoparticulate compositions having cationic surface stabilizers► Subscribe
9,034,875Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
8,937,150Anti-viral compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Drugs

Country Document Number Estimated Expiration
United Kingdom201400676► Subscribe
Canada2341805► Subscribe
Cyprus1116728► Subscribe
Japan2010018604► Subscribe
Israel154668► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
0731Netherlands► SubscribePRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
C0026France► SubscribePRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
2015 00015Denmark► SubscribePRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150119
12/008Ireland► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Cipla
Mallinckrodt
Boehringer Ingelheim
Queensland Health
UBS
QuintilesIMS
Covington
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot